The USS PRINCETON (LPH-5), an Essex-class aircraft carrier, was commissioned on 18 NOV 1945, too late for action in world War II. At first with the Atlantic Fleet and then with the Pacific, PRINCETON steam on post-war deployments and then was decommissioned on 20 JUN 1948 and placed in reserve.

LPH-5 is a psychedelic discovered by Emil Marcher-Rørsted, Jesper L. Kristensen and Anders A. Jensen at Danish biopharmaceutical company Lophora. [1] [2] It is a conformationally-restricted derivative of the phenethylamine 2C-TFM, also a hallucinogen, and acts as a potent agonist of the 5-HT 2A receptor (EC 50 = 3.2 nM, E max = 78%). [3]

USS Princeton (CV/CVA/CVS-37, LPH-5) was one of 24 Essex-class aircraft carriers built during and shortly after World War II for the United States Navy. The ship was the fifth US Navy ship to bear the name, and was named for the Revolutionary War Battle of Princeton.

The flight deck of USS Princeton (LPH-5) is the scene of a Sikorsky UH-34D Seahorse helicopter of Marine Medium Helicopter Transport Squadron 362 taking off to land Marines in the Vietcong- saturated Rung Sat Zone in South Vietnam, 26 March …

USS Princeton (CV/CVA/CVS-37, LPH-5) was one of 24 Essex-class aircraft carriers built during and shortly after World War II for the United States Navy. Princeton was commissioned in November 1945, too late to serve in World War II, but saw extensive service in the Korean War, in which she earned eight battle stars, and the Vietnam War.

Redesignated as attack aircraft carrier CVA 37 on October 1, 1952, and antisubmarine warfare aircraft carrier CVS 37 on January 1, 1954, the PRINCETON was initially scheduled for decommissioning after her 1957-58 cruise but instead was redesignated LPH 5 in March 1959 and converted into an amphibious assault ship.

Apr 22, 2024 · LPH-5 was found to be a potent partial agonist at the 5-HT 2A receptor (5-HT 2A R) and to exhibit pronounced selectivity for this receptor over the related 5-HT 2B and 5-HT 2C receptors in a range of functional assays.

Inspired by scientific research into the phenethylamine compound class, LPH-5 is an improvement over the classic psychedelics, synthetically designed to remove problematic characteristics of the known compound classes.

Jan 15, 2025 · After receiving approval from the European Medicines Agency (EMA) to commence its Phase I clinical study for LPH-5, Lophora has successfully completed an over $3 million capital raise to support this next phase and further bolster the …

LPH-5: a 5-HT2A receptor agonists Drug, Initially developed by Lophora ApS, Now, its global highest R&D status is Phase 1, Mechanism: 5-HT2A receptor agonists (Serotonin 2a (5-HT2a) receptor agonists), Therapeutic Areas: Nervous System Diseases, Active Indication: Depressive Disorder, Treatment-Resistant,Depressive Disorder, Active Org.: Lophora...